OpGen Inc. (NASDAQ: OPGN) stock gained by 2.83% at the last close whereas the OPGN stock price declines by 5.2% in the after-hours trading session. OpGen, Inc. is a precision medicine firm that uses molecular diagnostics and bioinformatics to aid in the fight against infectious disease.
OPGN stock’ Recent Development
Clinical results from a randomised controlled multicenter research were released by OpGen. On September 7, 2021, data from the Unyvero HPN was displayed in a virtual European Respiratory Society (ERS) conference, and on September 14, 2021, it was presented again at a webinar.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
“Multiplex Bacterial PCR in Bronchoalveolar Lavage (BAL) – Does It Impact Inappropriate Antibiotic Use?” was the topic of a webinar that discussed a study that looked at the clinical relevance and impact of the Unyvero panel in hospitalised adult patients. The people in the study had a suspicion of pneumonia and a clinical rationale for bronchoscopy, as well as a risk of Gram-negative bacterial infection.
About the study,
A total of 740 patients were screened, with 208 of them being randomly assigned to one of two groups: intervention or control. 100 patients were assigned to the intervention group, while 108 were assigned to the control group (BAL was analysed solely by conventional culture). Unyvero findings were provided 4 hours after the bronchoscopy and discussed with the attending physician handling the intervention group patients.
The outcomes of Unyvero in combination with antibiotic stewardship were found to be effective and safe in reducing time spent on inappropriate antibiotic medication in hospitalised patients with pneumonia who were at risk for Gram-negative rods.
Faranak Atrzadeh, OpGen’s Chief Marketing and Scientific Affairs Officer stated that,
The clinical value and practical influence of the Unyvero HPN panel are well demonstrated in this multicenter randomised interventional study. Unyvero is a quick and culture-independent thorough clinical instrument that aids in the diagnosis of bacterial infections or co-infections in the lower respiratory tract. It is being used in the hospital journey of extremely unwell patients, for whom speedy and accurate detection is very important in order to provide prompt and effective targeted antibiotic therapy. This is done to get the most out of the treatment while avoiding side effects and antibiotic resistance.